Medline Inc. (MDLN) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $44.52 (+0.11%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 9, 2026 | Ivan Feinseth | Tigress Financial | $60.00 | +34.8% |
| Feb 25, 2026 | Michael Cherny | Leerink Partners | $56.00 | +25.8% |
| Jan 21, 2026 | David Larsen | J.P. Morgan | $55.00 | +23.5% |
| Jan 12, 2026 | Ed Ridley-Day | Redburn Partners | $42.00 | -5.7% |
| Jan 12, 2026 | Elizabeth Anderson | Evercore ISI | $50.00 | +12.3% |
| Jan 12, 2026 | Jason Bednar | Piper Sandler | $50.00 | +12.3% |
| Jan 12, 2026 | Eric Coldwell | Robert W. Baird | $48.00 | +7.8% |
| Jan 12, 2026 | Sean Dodge | BMO Capital | $45.00 | +1.1% |
| Jan 12, 2026 | David Roman | Goldman Sachs | $49.00 | +10.1% |
| Jan 11, 2026 | Patrick Wood | Morgan Stanley | $48.00 | +7.8% |
Top Analysts Covering MDLN
MDLN vs Sector & Market
| Metric | MDLN | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.10 | 2.24 | 2.41 |
| Analyst Count | 10 | 8 | 18 |
| Target Upside | +9.7% | +1150.3% | +14.9% |
| P/E Ratio | 30.70 | 6.84 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $30.86B | $30.91B | $30.95B | 20 |
| 2027-03-31 | $7.57B | $7.60B | $7.64B | 7 |
| 2027-06-30 | $8.02B | $8.06B | $8.10B | 7 |
| 2027-09-30 | $8.27B | $8.30B | $8.35B | 7 |
| 2027-12-31 | $9.20B | $9.24B | $9.30B | 7 |
| 2028-03-31 | $8.21B | $8.25B | $8.30B | 6 |
| 2028-06-30 | $8.59B | $8.63B | $8.68B | 6 |
| 2028-09-30 | $8.84B | $8.88B | $8.93B | 6 |
| 2028-12-31 | $9.81B | $9.85B | $9.91B | 6 |
| 2029-12-31 | $38.25B | $38.46B | $38.74B | 15 |
| 2030-12-31 | $40.84B | $41.06B | $41.36B | 15 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $1.41 | $1.46 | $1.51 | 16 |
| 2027-03-31 | $0.35 | $0.35 | $0.35 | 10 |
| 2027-06-30 | $0.39 | $0.39 | $0.39 | 6 |
| 2027-09-30 | $0.41 | $0.41 | $0.41 | 7 |
| 2027-12-31 | $0.50 | $0.50 | $0.50 | 6 |
| 2028-03-31 | $0.40 | $0.40 | $0.41 | 7 |
| 2028-06-30 | $0.46 | $0.46 | $0.46 | 7 |
| 2028-09-30 | $0.45 | $0.45 | $0.46 | 12 |
| 2028-12-31 | $0.56 | $0.56 | $0.57 | 7 |
| 2029-12-31 | $2.11 | $2.12 | $2.14 | 3 |
| 2030-12-31 | $2.37 | $2.39 | $2.41 | 3 |
Frequently Asked Questions
What is the analyst consensus for MDLN?
The consensus among 10 analysts covering Medline Inc. (MDLN) is Buy with an average price target of $48.59.
What is the highest price target for MDLN?
The highest price target for MDLN is $60.00, set by Ivan Feinseth at Tigress Financial on 2026-03-09.
What is the lowest price target for MDLN?
The lowest price target for MDLN is $42.00, set by Ed Ridley-Day at Redburn Partners on 2026-01-12.
How many analysts cover MDLN?
10 analysts have issued ratings for Medline Inc. in the past 12 months.
Is MDLN a buy or sell right now?
Based on 10 analyst ratings, MDLN has a consensus rating of Buy (2.10/5) with a +9.7% upside to the consensus target of $48.59.
What are the earnings estimates for MDLN?
Analysts estimate MDLN will report EPS of $1.46 for the period ending 2026-12-31, with revenue estimated at $30.91B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.